PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jbcThe Journal of Biological Chemistry
 
J Biol Chem. 2011 August 19; 286(33): 29053–29062.
Published online 2011 June 17. doi:  10.1074/jbc.M111.259150
PMCID: PMC3190713

Clostridium difficile Has an Original Peptidoglycan Structure with a High Level of N-Acetylglucosamine Deacetylation and Mainly 3-3 Cross-links*An external file that holds a picture, illustration, etc.
Object name is sbox.jpg

Abstract

The structure of the vegetative cell wall peptidoglycan of Clostridium difficile was determined by analysis of its constituent muropeptides with a combination of reverse-phase high pressure liquid chromatography separation of muropeptides, amino acid analysis, mass spectrometry and tandem mass spectrometry. The structures assigned to 36 muropeptides evidenced several original features in C. difficile vegetative cell peptidoglycan. First, it is characterized by a strikingly high level of N-acetylglucosamine deacetylation. In addition, the majority of dimers (around 75%) contains A2pm3 → A2pm3 (A2pm, 2,6-diaminopimelic acid) cross-links and only a minority of the more classical Ala4 → A2pm3 cross-links. Moreover, a significant amount of muropeptides contains a modified tetrapeptide stem ending in Gly instead of d-Ala4. Two l,d-transpeptidases homologues encoding genes present in the genome of C. difficile 630 and named ldtcd1 and ldtcd2, were inactivated. The inactivation of either ldtcd1 or ldtcd2 significantly decreased the abundance of 3-3 cross-links, leading to a marked decrease of peptidoglycan reticulation and demonstrating that both ldtcd1-and ldtcd2-encoded proteins have a redundant l,d-transpeptidase activity. The contribution of 3-3 cross-links to peptidoglycan synthesis increased in the presence of ampicillin, indicating that this drug does not inhibit the l,d-transpeptidation pathway in C. difficile.

Keywords: Bacteria, Biosynthesis, Cell Wall, Mass Spectrometry (MS), Mutant, Clostridium difficile, l,d-Transpeptidase, Ampicillin, Peptidoglycan

Introduction

Clostridium difficile, a Gram-positive spore-forming bacterium, is the major cause of intestinal diseases associated with antibiotic therapy such as ampicillin, clindamycin, and cephalosporins, which disrupt the barrier intestinal flora and allow C. difficile colonization (1, 2). Clinical manifestations range from asymptomatic colonization or mild diarrhea to pseudomembranous colitis (3). The main virulence factors have been identified as toxin A and B (4). Recent outbreaks have led to increasing morbidity and mortality and have been associated with a new highly virulent strain (BI/NAP1/027) of C. difficile. Antibiotic treatment of C. difficile-associated disease requires metronidazole or vancomycin therapy.

Peptidoglycan (PG)2 of Gram-positive bacteria usually consists of long linear glycan strands cross-linked by short stem peptides (5, 6). PG is usually connected by 4-3 cross-links catalyzed by d,d-transpeptidases, which belong to the penicillin-binding proteins and whose substrate is the peptidyl d-Ala4-d-Ala5 extremity of PG precursors. d,d-Transpeptidases are the essential targets of β-lactams antibiotics, which are structural analogues of the d-Ala4-d-Ala5 terminus precursor molecule (7, 8). Alternatively, PG can be connected by 3-3 cross-links generated by l,d-transpeptidases (9), which were originally detected in Enterococcus faecium (Ldtfm) (10) and then in other Gram-positive bacteria(11, 12), in mycobacteria (1315), and in Escherichia coli (16, 17). Ldts use acyl donors containing a tetrapeptide stem (9) and were consequently expected to confer resistance to β-lactams (10, 18).

Another possible variation of the PG structure is the occurrence of N-deacetylation or O-acetylation of glycan strands, either on GlcNAc or on MurNAc residues (19, 20). N-Deacetylation in Listeria monocytogenes (21) or Streptococcus pneumoniae (22) and O-acetylation in Staphylococcus aureus have been linked to lysozyme resistance (23).

The PGs of C. difficile should have some specificities regarding the effect of antibiotics inhibiting PG biosynthesis; C. difficile, although susceptible to β-lactams, exhibits higher minimal inhibitory concentrations than in other Clostridium species such as Clostridium perfringens (24), and it also displays a preserved susceptibility to vancomycin despite the presence of a vanG-like operon (25). However, little is known about the PG structure and biosynthesis in C. difficile. In the present work, we report the fine structure of C. difficile vegetative PG. This structure reveals the presence of a high proportion of non-acetylated glucosamine residues on the glycan strands and the unusual abundance of 3 → 3 peptide cross-links generated by l,d-transpeptidation. Mutations of two putative l,d-transpeptidase genes demonstrate the role of the corresponding proteins in the formation of 3 → 3 cross-links. The participation of the l,d-transpeptidases to peptidoglycan cross-linking increases in the presence of ampicillin, indicating that this drug does not inhibit the l,d-transpeptidation pathway in C. difficile.

EXPERIMENTAL PROCEDURES

Bacterial Strains and Culture Conditions

The bacterial strains used in this study are listed in supplemental Table S1. C. difficile 630, which is a virulent and multidrug-resistant isolated from an outbreak in Switzerland (25), and C. difficile 630Δerm (26), which is a spontaneously cured derivative of strain 630 and allows selection of ClosTron mutants, were used in all experiments. C. difficile strains were routinely cultured on blood agar (Oxoid), BHI agar (Difco), or BHI broth (Difco) at 37 °C in an anaerobic environment (80% N2, 10% CO2, and 10% H2). When necessary, C. difficile culture media were supplemented with cefoxitin (25 mg/liter), thiamphenicol (15 mg/liter), or erythromycin (5 mg/liter). E. coli Top10 (Invitrogen) was used for cloning and plasmid propagation, and E. coli HB101 (RP4) was used as the conjugative donor strain employed in the creation of C. difficile mutants. E. coli strains were cultured aerobically at 37 °C in LB broth or LB agar (MP Biomedicals) containing chloramphenicol (25 mg/liter). When required, ampicillin (100 mg/liter) was added.

Susceptibility Testing

Minimal inhibitory concentrations for ampicillin and vancomycin against C. difficile strains were determined by the E-test method (Bio-Merieux) from bacterial suspensions at 3 Mc-Farland turbidity.

Peptidoglycan Structure Analysis

C. difficile PG structure was analyzed by reverse-phase high performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry as described previously for Lactococcus lactis (27) with some modifications. Briefly, PG was extracted from an exponential culture (A600 of 0.3) on BHI with boiling sodium dodecyl sulfate and was deproteinized by treatment with Pronase and trypsin. The material was treated with DNase (50 μg/ml) and RNase (50 μg/ml) and then incubated with 48% hydrofluoric acid at 4 °C for 16 h to remove cell-wall teichoic acids. Purified PG was digested with mutanolysin (Sigma), and the soluble muropeptides were reduced with sodium borohydride. They were then separated by RP-HPLC using a Hypersil octyldecyl silane column (C18; 250 × 4.6 mm; 5 μm; ThermoHypersil-Keystone) at 50 °C by the method of Courtin et al. (27). Fractions containing the main peaks were analyzed by MALDI-TOF mass spectrometry with a Voyager DE STR mass spectrometer (Applied Biosystems) and α-cyano-4-hydroxycinnamic acid matrix.

Amino Acid and Amino Sugar Composition Analysis

Amino acid and amino sugar composition analysis of muropeptides after acid hydrolysis was performed using the previously described Waters Picotag method (27).

Tandem Mass Spectrometry

For MS-MS structural analysis, muropeptides were desalted on a Betasil C18 column (4.6 × 250 mm, Thermo Electron Corp.) with acetonitrile/formic acid buffer system and dried with speed-vacuum. Samples were solubilized in 2% acetonitrile, 0.1% formic acid in milliQ water (1 μl for 1 milliabsorbance unit detected at 214 nm in the previous HPLC system). Each purified muropeptide was injected and analyzed at a flow rate of 0.2 μl/min on the mass spectrometers (LTQ-ETD or LTQ-Orbitrap, Thermo Fisher) located on the PAPPSO platform (Institut National de la Recherche Agronomique, France).

General DNA Techniques

Chromosomal DNA extraction from C. difficile colonies was performed using the InstaGene Matrix kit (Bio-Rad). PCRs were done with a reaction volume of 25 μl by using GoTaq Green Master (Promega) or Advantage II Polymerase Mix (BD Biosciences). The primers used (Eurofins MWG Operon) are listed in supplemental Table S2. PCR products and plasmids were purified using a NucleoSpin Extract II kit and a Nucleospin plasmid kit (Macherey-Nagel), respectively.

Construction of C. difficile ldtcd1 and ldtcd2 Single Mutants by Using the ClosTron System

The ClosTron system was used as described previously (28) in conjunction with the commercially available TargeTron gene knock-out system kit (Sigma). Briefly, the algorithm available on the TargeTron Design Site was used to identify intron insertion sites within ldtcd1 and ldtcd2. The primers (supplemental Table S2) designed by the algorithm to retarget the group II intron on pMTL007 to ldtcd1 and ldtcd2 were used with the EBS universal primer and intron template DNA to generate a 353-bp DNA fragment for each gene by overlap PCR according to the manufacturer's instructions. The two resultant PCR products were cloned into the HindIII and BsrGI restriction sites of pMTL007, and the constructs were transformed into E. coli TOP10. The fidelity of the cloned inserts was verified by DNA sequencing using pMTL007-specific primers pMTLseq-F and pMTLseq-R (supplemental Table S2). pMTL007::Cdi-ldtcd1-1231s and pMTL007::Cdi-ldtcd2-480s plasmids (supplemental Table S2) retargeted the group II intron to insert into ldtcd1 and ldtcd2 genes in the sense orientation immediately after the 1231th and 480th nucleotides in the coding sequence, respectively, thus within the DNA sequence encoding the catalytic domain. These derivative pMTL007 plasmids were transformed into the conjugative donor E. coli HB101 (RP4) and then transferred via conjugation into the C. difficile 630Δerm. Successful C. difficile transconjugants were selected by subculturing on BHI agar containing cefoxitin (25 mg/liter) and thiamphenicol (15 mg/liter). Then, the integration of the group II intron RNA into the ldtcd1 and ldtcd2 genes was selected by plating onto BHI agar with erythromycin (5 mg/liter). Erythromycin-resistant (and thiamphenicol-sensitive) C. difficile colonies are produced after plasmid loss and insertion of the group II intron into the chromosome, which is accompanied by splicing out of the group I intron from the ermB retrotransposition-activated marker (RAM). Moreover, genomic DNA of erythromycin-resistant transconjugants was isolated and subjected to PCR using primers flanking ldtcd1ldtcd1-F and ldtcd1-R (supplemental Table S2) and primers flanking ldtcd2 ldtcd2-F and ldtcd2-R (supplemental Table S2) to verify that the group II intron had inserted into the correct target gene. In addition to Erm resistance being demonstrated phenotypically, confirmatory PCR using the RAM-F/RAM-R primer pair (supplemental Table S2) was also performed.

Construction of a C. difficile ldtcd1 and ldtcd2 Double Mutant by Using the ClosTron System

The ldtcd1-ldtcd2 double mutant was constructed from the ldtcd2 single mutant. Retargeted plasmid pMTL007::Cdi-ldtcd1-1231s was transferred via conjugation, as previously, into the C. difficile 630Δerm ldtcd1::intron-erm. C. difficile transconjugants were selected by subculturing on BHI agar containing thiamphenicol (15 μg/ml). The double mutant could not be selected by erythromycin resistance, as a functional ermB gene was carried in the single mutant strain. Consequently, intron insertion was directly screened by PCR. Genomic DNA was isolated from single thiamphenicol-resistant colonies and subjected to PCR using primer ldtcd1-F with the EBS universal primer (supplemental Table S2) to determine the presence of an intron insertion. As low frequency of intron insertion was detected within the first tested transconjugants, several re-streaking of colonies onto fresh BHI agar containing thiamphenicol (15 mg/liter) were necessary. Positive individual colonies were tested by PCR using ldtcd1-flanking primers (supplemental Table S2).

RESULTS

Vegetative Cell Wall Peptidoglycan Composition of C. difficile 630

Muropeptides of C. difficile 630 were obtained from PG digestion by muramidase mutanolysin, reduced with sodium borohydride, and separated by RP-HPLC. The HPLC muropeptide profile is presented on Fig. 1A. PG extracted from exponential and stationary phases cultures (A600 nm of 0.35 and 1.4, respectively) displayed similar elution profiles of muropeptides. Amino acid and amino sugar composition analysis of the major peaks 4, 7, 11a, and 15a after acid hydrolysis, using the Waters Picotag method (27), confirmed muropeptides with Ala, Glu, A2pm (2,6-diaminopimelic acid), and in some cases Gly (data not shown). The mass of 31 peaks was determined by MALDI-TOF mass spectrometry, and the structure of 36 muropeptides was deduced (Table 1). The structure of muropeptides and their respective abundances, expressed as percentages of the area under all of the muropeptides peaks, are presented in Table 1. Monomers, dimers, and trimers represented 35.1, 56.6, and 8.3% of the total Muropeptides, respectively, and the cross-linking index was calculated to be 33.8% (Table 2). AnhydroMurNAc muropeptides, proposed to be present at the extremity of glycan chains (29), were detected in low amounts (peaks 30 and 31) (Table 1).

FIGURE 1.
RP-HPLC separation of muropeptides from C. difficile 630 (A) and from C. difficile 630Δerm ldtcd1::intron-erm (B). Peaks numbers refer to Table 1. A few peaks contain two muropeptides identified as a and b in Table 1. New muropeptides identified ...
TABLE 1
Structures, molecular masses, and proportions of muropeptides from C. difficile 630 grown in BHI, in BHI plus ampicillin, and from ldtcd1, ldtcd2, and ldtcd1ldtcd2 mutant strains
TABLE 2
Relative distribution (%) of muropeptides in C. difficile 630 grown in BHI, in BHI plus ampicillin, and from ldtcd1, ldtcd2, and ldtcd1ldtcd2 mutant strains

N-Deacetylation of Peptidoglycan Glycan Strands

Among the muropeptides identified, a high proportion had one or more 42-Da mass defects compared with the expected calculated molecular masses. This 42-Da mass defect suggests a lack of one acetyl group on an amino sugar. To determine if this N-deacetylation occurs on GlcNAc or MurNAc, the major dimer peak 15a (m/z 855.9, z = 2), containing a muropeptide dimer with two N-deacetylations, was subjected to MS-MS analysis (Fig. 2). Among the muropeptide fragment ions, fragments with an m/z of 775.3 (z = 2) and m/z of 694.9 (z = 2) corresponded to the loss of 1 (mass defect of 161 Da) or 2 glucosamines, respectively. In contrast, no fragment corresponding to the loss of one GlcNAc (mass defect of 203 Da) was observed. In addition, fragments resulting from the loss of one MurNAc (mass defect of 277 Da) were observed, whereas no fragment corresponding to the loss of one muramic acid (mass defect of 235 Da) was visualized. These results indicate that muropeptide 15a contains two glucosamine residues instead of GlcNAc residues. MS-MS analyses of the main monomers (muropeptides 4 and 7) and subsequent MS-MS analyses of the main dimers realized in this study (muropeptides 10, 11a, 11b, 13, 14, 15a, 15b, 16, 17, 19, 21) were in agreement with this result, indicating that the 42-Da defect always corresponds to N-deacetylation of glucosamine. Overall, 93% of the GlcNAc residues were N-deacetylated in the PG of C. difficile.

FIGURE 2.
Sequencing of muropeptide 15a by MS-MS. The muropeptide was desalted and analyzed by MS-MS with a MALDI source. The parental ion (m/z 855.85 with z = 2) (A) and the fragment ion with m/z of 911.4 (B) were selected for fragmentation. Inferred structure ...

Relative Proportions of 3-3 and 4-3 Cross-links in the Peptidoglycan

On the basis of MALDI-TOF mass determination, muropeptide 11b was proposed to have a dimer structure with two tripeptide stems, strongly suggesting a cross-link between two A2pm residues (3-3 cross-link), generated by l,d-transpeptidation. This structure was confirmed by MS-MS analysis, as a fragment ion with m/z of 363.2 and corresponding to an A2pm- A2pm dipeptide was observed (Fig. 3). Among dimers, muropeptides 5b had also two tripeptide stems and clearly contained the unusual A2pm3 → A2pm3 cross-link.

FIGURE 3.
Sequencing of muropeptide 11b by MS-MS. The muropeptide was desalted and analyzed by MS-MS with a MALDI source. The parental ion (m/z 820.4 with z = 2) (A) and the fragment ion m/z of 840.3 (B) were selected for fragmentation. Inferred structure is represented ...

As cross-links generated by l,d-transpeptidation were detected in the PG of C. difficile, MS-MS analysis of the main dimers were performed to differentiate d-Ala4 → A2pm3 and A2pm3 → A2pm3 cross-links generated by transpeptidases of d,d and l,d specificities, respectively. Major dimeric muropeptide 15a may contain either 4 → 3 (donor tetrapeptide stem and acceptor tripeptide stem) or 3 → 3 cross-links (donor tripeptide stem and acceptor tetrapeptide stem). The fragmentation pattern of the muropeptide 15a revealed a 3 → 3 cross-link as 1 alanine residue was lost (mass defect of 89 Da) from the C-terminal end of the acceptor tetrapeptide stem. Moreover, a fragment ion with m/z of 474.3 corresponding to Glu-A2pm-A2pm was observed, confirming the A2pm3 → A2pm3 cross-link (Fig. 2). Muropeptides 10, 13, 14, 16, and 17 have also a dimer structure with a tripeptide stem and a tetrapeptide stem. Interestingly, MS-MS analysis of these muropeptides revealed the presence of an A2pm3 → A2pm3 cross-link in all cases.

Seven identified muropeptides contain glycine in their composition (muropeptides 3, 4, 5a, 9, 11a, 15b, and 22b). Analysis of muropeptide 11a by MS-MS showed that Gly was linked with A2pm (supplemental Fig. S1). Moreover, the fragmentation pattern indicated that the muropeptide 11a harbors an A2pm3 → A2pm3 cross-link generated by l,d-transpeptidation Thus, glycine does not constitute an interpeptide bridge with the adjacent peptide subunit but is located at position 4 of a peptide stem instead of d-Ala. This result suggests that l,d-transpeptidases of C. difficile 630 could hydrolyze d-Ala4 and exchange this residue with Gly, as shown in E. coli (17). In this way dimers with a disaccharide tripeptide stem and a disaccharide tetrapeptide stem ending in Gly (peaks 5a, 9, and 11a) were considered to contain an A2pm3 → A2pm3 cross-link. Conversely, MS-MS analysis of the dimer 15b, which harbors a tetrapeptide stem and a tetrapeptide ending in Gly, was shown to contain an Ala4 → A2pm3 cross-link (data not shown). Dimers 18, 19, 20, 21, and 31 were proposed to have a dimer structure with a donor tetrapeptide stem and an acceptor tetrapeptide stem, suggesting they contained 4 → 3 cross-links. As expected, the fragmentation patterns of muropeptides 19 and 21 showed that the cross-link was of the Ala4 → A2pm3 type (supplemental Fig. S2 and data not shown). Muropeptides 18, 20, and 31 were considered to also contain 4 → 3 cross-links.

Thus, the PG of C. difficile contains both d-Ala4 → A2pm3 cross-links generated by d,d-transpeptidation and A2pm3 → A2pm3 cross-links generated by l,d-transpeptidation. For the whole muropeptides, the proportion of dimers generated by l,d-transpeptidation and d,d-transpeptidation were about 41.3 and 15.3% that of the area of all peaks, respectively (Table 2). Therefore, 73% of the cross-links of the dimeric muropeptides were generated by l,d-transpeptidation.

Inactivation of Two Putative l,d-Transpeptidases Encoding Genes Using the ClosTron System

The genome of C. difficile contains a gene named ldtcd1(CD2963) that encodes a protein of 469 residues, related to Ldtfm of E. faecium (overall amino acid identity, 29%; amino acid identity for the catalytic domain, 38%). The two proteins display the same domain composition, including a putative transmembrane domain, two putative PG binding domains belonging to PG binding 4 superfamily, and the catalytic domain with the SXGC conserved motif (Fig. 4) (10, 30). Two others proteins, Ldtcd2 (CD2713) and CD3007, encoded by the C. difficile genome, exhibit significant sequence identity with the Ldtfm catalytic domain (25 and 23%, respectively), including the SXGC motif (Fig. 4). Unlike Ldtfm and Ldtcd1, Ldtcd2 and CD3007 have no hydrophobic regions that could act as membrane anchors but contain a putative peptidoglycan binding domain consisting of three CWB-2 modules or two SH3 modules respectively.

FIGURE 4.
Domain composition of L,d-transpeptidases from E. faecium and C. difficile. Hatched boxes represent hydrophobic regions that could act as membrane anchors. Gray and black boxes represent putative peptidoglycan binding domain and the catalytic domain respectively. ...

To study the functions of the ldtcd1and ldtcd2 genes, the ClosTron system was used to create insertional mutants of C. difficile 630Δerm in which either the ldtcd1 or ldtcd2 gene or both ldtcd1 ldtcd2 genes were inactivated. Insertion of the group II intron into the target genes was verified by PCR using specific internal primers (supplemental Table S2 and Fig. S3). For unknown reasons and despite multiple attempts, it was not possible to inactivate the CD3007 encoding gene using the ClosTron system.

Effect of ldtcd1 Mutation, ldtcd2 Mutation, or ldtcd1-ldtcd2 Double Mutation on the Peptidoglycan Structure

The growth rate of the different mutant strains was not impaired when compared with that of the parental strain. To determine the role of the putative l,d-transpeptidase Ldtcd1, the PG structure of the corresponding mutant strain was determined and compared with the muropeptide profile of the C. difficile 630Δerm parental strain (of note, the muropeptide profile of the C. difficile 630Δerm strain was the same as that of C. difficile 630; data not shown).

The RP-HPLC muropeptide profile from ldtcd1mutant strain (Fig. 1B) exhibited a markedly different profile from that of the 630Δerm parental strain. The overall composition of the PG from ldtcd1 shows a significant decrease in muropeptide dimers (56.6 to 29.9%) and an increase in muropeptide monomers (35.1 to 49.8%), whereas the proportion of muropeptide trimers was not significantly affected (Table 2). Among the dimers, a marked decrease (from 41.3 to 19% of all the peaks) of the muropeptides containing a 3 → 3 cross-link was observed. The proportion of dimers containing a 4 → 3 cross-link was only slightly decreased (Table 2). A new muropeptide termed Y (10.5% of all the peaks) and two new minor muropeptides termed X (0.9% of all the peaks) and Z (1.8% of all the peaks) were identified in the HPLC profile of the ldtcd1mutant strain (Table 1). According to its mass (m/z 1779.5) and MS-MS spectra (Fig. 5), the muropeptide Y could correspond to a dimer with two tetrapeptide stems without a cross-link between the two peptide chains and with a tetrasaccharide chain. Composition analysis fits with the proposed structure as only one MurOHNAc was detected for two Glu (data not shown). The absence of cleavage of the tetrasaccharide chain by mutanolysin could result from a modification of the central MurNAc residue without a change of its mass or from the presence of another type of glycosidic linkage between MurNAc and GlcNAc. The minor muropeptide X (m/z 1708.5) represents a dimer with a disaccharide tripeptide stem and a disaccharide tetrapeptide stem. The fragmentation pattern of this dimer revealed the same structural features than the muropeptide Y (data not shown). By analogy, the structure of the muropeptides Z was assigned to be a trimer with two tetrapeptide stems and a tripeptide stem containing one cross-link generated by transpeptidation and one bond between MurNAc and GlcNAc residues. Consequently, the overall cross-linking index was only 18.2% in the ldtcd1mutant strain, compared with 33.8% of the wild type (Table 2). Taken together, these results suggest that Ldtcd1 could function as a l,d-transpeptidase involved in the formation of A2pm3 → A2pm3 cross-links.

FIGURE 5.
Sequencing of muropeptide Y by MS-MS. The muropeptide was desalted and analyzed by MS-MS with a MALDI source. The parental ion (m/z 890.3 with z = 2) (A) and the fragment ion with m/z of 810.1 (z = 2) (B) were selected for fragmentation. Inferred structure ...

The muropeptide profile of the ldtcd2 mutant was close to that of the ldtcd1 mutant (data not shown). Indeed, comparison of the PG profile of ldtcd2 mutant with that of the wild type strain revealed an increase of monomers that occurred to the detriment of dimers. The muropeptides involved in this variation of abundance were exactly the same as those listed for the ldtcd1 mutant and led to a significant decrease of cross-links generated by l,d-transpeptidation. Moreover, muropeptides X, Y, and Z identified in the ldtcd1 mutant strain were also detected in the PG composition of the ldtcd2 mutant. However, changes were generally less pronounced in the ldtcd2 mutant strain when compared with the ldtcd1 mutant (Tables 1 and and22).

Cross-link formation of A2pm3 → A2pm3 type was decreased but not abolished either in the ldtcd1 or ldtcd2 mutant strain. This result suggests that there is some functional redundancy, so that Ldtcd1 and Ldtcd2 proteins could have a mutually partial compensatory role. Thus, we determined the muropeptide profile of a ldtcd1 ldtcd2 double mutant strain. Interestingly, no obvious differences were observed when compared with that of the ldtcd1 mutant strain (Tables 1 and and2).2). This suggests the involvement of at least a third l,d-transpeptidase (possibly CD3007) able to partially compensate for the lack of both Ldtcd1 and Ldtcd2.

Impact of Ampicillin on C. difficile 630 Peptidoglycan Structure

The impact of ampicillin on PG structure was evaluated in C. difficile 630 grown in the presence of ampicillin at the maximum concentration allowing growth (1.0 mg/liter) (data not shown). Ampicillin did not modify the relative proportion of muropeptide monomers, dimers, and trimers (Table 1). However, ampicillin altered the balance between cross-links generated by d,d-transpeptidation and l,d-transpeptidation. Partial inhibition of the d,d-transpeptidases by ampicillin decreased the proportion of dimers containing a d-Ala4 → A2pm3 cross-link (from 15.3 to 7.4% of all the peaks), leading to an increase of dimers generated by l,d-transpeptidation (from 41.3 to 48.6% of all the peaks) (Table 2). Thus, 87% of the dimers were cross-linked by l,d-transpeptidation in the ampicillin-treated strain. This result suggests that l,d-transpeptidases of C. difficile are ampicillin-insensitive. However, C. difficile remains susceptible to ampicillin, indicating that d,d-transpeptidases generating 4-3 cross-links are essential for PG assembly.

Impact of Vancomycin on C. difficile 630 Peptidoglycan Structure

The genome of C. difficile 630 harbors a vanG-like operon structure. The vanG operon is responsible for moderate resistance to vancomycin in Enterococcus faecalis (31), but the vanG-like operon does not confer vancomycin resistance in C. difficile (25). To investigate if vancomycin could, either directly or through the induction of the vanG-like operon, interfere with the l,d-transpeptidation pathway, we extracted the PG from exponential cultures of C. difficile grown in the presence of a subinhibitory concentration of vancomycin (1/4 minimal inhibitory concentration 0.375 mg/liter) and analyzed its structure by RP-HPLC. The muropeptide profile was exactly the same as that of the untreated strain, indicating that vancomycin does not alter the balance between l,d- and d,d-transpeptidation mechanisms.

DISCUSSION

This work reports, for the first time to our knowledge, the composition and structure of PG of C. difficile. The most prevalent muropeptide monomer (peak 7, 26.2% of all peaks) (Fig. 1 and Table 1) represents the basic disaccharide tetrapeptide subunit, whose tetrapeptide stem consists of the usual l-Ala-d-Glu-A2pm-d-Ala. Of note, some muropeptides (monomer 2 and monomer 10, Table 1) lacked a GlcNAc residue. They could result from cleavage by the previously described Acd glucosaminidase (32). Schleifer and Kandler (33) previously reported the amino acid composition of PG of many species of the genus Clostridium. Most species contained only meso-A2pm, Ala, and Glu, although C. perfringens revealed l,l-A2pm instead of meso-A2pm and additional Gly in the interpeptide bridge, and Clostridium innocuum contained l-Lys instead of A2pm. C. difficile was not reported in this previous work, but based on our amino acid content detection and on the phylogenetic link of C. difficile with Clostridium bifermentans and Clostridium sordellii (34), which contains meso-A2pm (33), PG of C. difficile very likely contains meso-A2pm.

A high proportion of N-deacetylation of the glycan strands was observed in C. difficile (Table 1). This structural variation occurred only on GlcNAc residues (Fig. 2), whose 93% were N-deacetylated, whereas MurNAc residues remained fully acetylated. Nonacetylated glucosamine (GlcN) or muramic acid (MurN) residues have already been reported, but at a lower rate, in some Gram-positive bacteria (29) such as Bacillus anthracis (35), Bacillus subtilis (36), S. pneumoniae (37), or L. monocytogenes (21). The presence of these non-acetylated amino sugars confers resistance to lysozyme, an exogenous muramidase, which normally cleaves PG between the glycosidic β1–4-linked residues of GlcNAc and MurNAc. The N-deacetylation of the GlcNAc residues is achieved by PgdA deacetylases, which have been shown to provide a protective role against host defenses in L. monocytogenes (21) and S. pneumoniae (22). Further studies should be performed to examine the impact of GlcNAc N-deacetylation on lysozyme resistance in C. difficile. Our in silico analysis of the genome sequence of C. difficile 630 revealed the presence of 10 putative polysaccharide deacetylases encoding genes belonging to the carbohydrate esterase family CE4. Ten putative polysaccharide deacetylase-encoding genes were also identified in the B. anthracis and Bacillus cereus genomes (38), which exhibit important N-deacetylation levels (29, 35).

An important and unexpected feature of the composition of C. difficile PG is the abundance of A2pm3 → A2pm3 cross-links generated by l,d-transpeptidation. This unusual type of cross-link was originally detected in E. coli, in which it represents about 5 and 12% of the total muropeptide content in the exponential and stationary growth phases, respectively (39) and more recently in several Gram-positive bacteria (11, 13, 14, 18). In Mycobacterium tuberculosis, the majority of the cross-links are generated by d,d-transpeptidation during exponential growth, whereas 80% of the cross-links are generated by l,d-transpeptidation during the stationary growth phase (13). In the present work the PG structure of C. difficile from the stationary and exponential growth phases revealed a similar profile, characterized by a large proportion of 3 → 3 cross-links, suggesting that the l,d-transpeptidases of C. difficile constitutively contribute to PG cross-linking. To our knowledge, this predominant contribution of l,d-transpeptidases to PG cross-linking has never been previously reported in low GC% Gram-positive bacteria.

We identified three putative l,d-transpeptidases encoding genes, named ldtcd1, ldtcd2, and CD3007 in the genome of C. difficile 630 and obtained ldtcd1, ldtcd2 single and double mutants strains. These genes are significantly transcribed during exponential growth in the wild type strain but are not transcriptionally up-regulated in response to loss of one or more l,d-transpeptidase-encoding genes in the different mutant strains (data not shown). The PG profiles of the wild type and different l,d-transpeptidase mutant strains showed significant differences. The mutant strains show a marked decrease in the abundance of dimers to the partial benefice of monomers. Among the dimers, the proportion of muropeptides cross-linked by d,d-transpeptidation is slightly affected, whereas the proportion of muropeptides generated by l,d-transpeptidation is reduced by about one-half. These modifications lead to a marked decrease of the cross-linking index. Thus, both Ldtcd1 and Ldtcd2 constitute functional l,d-transpeptidases in C. difficile. Of note, mutation of either ldtcd1 or ldtcd2 reduces but does not abolish the formation of A2pm3 → A2pm3 cross-links, and the muropeptide profile of a double mutant strain lacking both Ldtcd1 and Ldtcd2 is similar to that of the single mutant strains. These data indicate the presence of at least a third functional l,d-transpeptidase (possibly CD3007) that could partially compensate for the loss of Ldtcd1 and Ldtcd2 encoding genes.

Another notable feature of the PG structure of Ldtcd1 and Ldtcd2 mutants is the presence of three new muropeptides. Two of them have a dimeric structure with one tetrapeptide and one tripeptide side chain or two tetrapeptide side chains, whereas the third has a trimeric structure with one tripeptide and two tetrapeptide side chains. Interestingly, MS-MS sequencing of the new muropeptide dimers revealed the absence of a peptide cross-link but the presence of a bond between the MurNAc residue of the first disaccharide and the GlcNAc residue of the second disaccharide. It appears that the glycosidic bond between the MurNAc and GlcNH2 residues of the new muropeptides are insensitive to the mutanolysin activity. It was reported in B. subtilis that the glycosidic bond adjacent to a muramic δ-lactam in endospore PG is resistant to the action of muramidases (40, 41). However, in C. difficile, the mechanism of the mutanolysin resistance remains unclear and could result from a change in the MurNAc residue or from the formation of an unusual glycosidic bond.

The relative contribution of d,d-transpeptidation and l,d-transpeptidation for cross-linking has been related to ampicillin resistance in E. faecium (42). Partial inhibition of the d,d-transpeptidases by ampicillin increased the proportion of the dimeric muropeptides containing an A2pm3 → A2pm3 cross-link, suggesting that the l,d-transpeptidation pathway is insensitive to ampicillin in C. difficile. However, despite a predominant amount of 3-3 cross-links, C. difficile remains susceptible to ampicillin (although minimal inhibitory concentration values are higher than in species such as C. perfringens) (24). These observations suggest that the residual d,d-transpeptidase activity of penicillin-binding proteins detected in the presence of ampicillin could be essential to the PG assembly of C. difficile.

The activity of the Ldtfm l,d-transpeptidase in E. faecium is limited by the production of its tetrapeptide substrate (10), which results from the activity of a β-lactam insensitive metallo-d,d-carboxypeptidase named DdcY and belonging to the VanY superfamily (43). In C. difficile, the impact of ampicillin on the PG structure suggests the presence of a homologous gene to the DdcY encoding gene responsible for the tetrapeptide substrate production. The genome of C. difficile harbors three putative β-lactams-insensitive d,d-carboxypeptidases, generating tetrapeptide substrate. Among them, VanXYG is encoded by a member of the vanG-like operon that does not confer resistance to vancomycin. Further studies should be considered to investigate the involvement of the different d,d-carboxypeptidases in the tetrapeptide substrate production, which is critical for the main 3-3 cross-linking in C. difficile. This study shows that C. difficile displays an original PG structure including a high level of N-deacetylated GlcNAc and a predominant proportion of 3 → 3 cross-links generated by at least two l,d-transpeptidases.

Supplementary Material

Supplemental Data:

Acknowledgments

We thank Nigel P. Minton and John T. Heap as creators of the ClosTron gene knockout system and Bruno Dupuy for the gift of the strain 630Δerm of C. difficile.

*This work was supported by the University of Rouen and Rouen University Hospital.

An external file that holds a picture, illustration, etc.
Object name is sbox.jpgThe on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1 and S2 and Figs. S1–S3.

2The abbreviations used are:

PG
peptidoglycan
RAM
retrotransposition-activated marker
A2pm
2,6-diaminopimelic acid
GlcNH2
N-deacetylated GlcNAc
MurOHNAc
N-acetylmuramicitol
MurNac
N-acetylmuramic acid
GlcNac
N-acetylglucosamine.

REFERENCES

1. Viswanathan V. K., Mallozzi M. J., Vedantam G. (2010) Gut Microbes 1, 234–242 [PMC free article] [PubMed]
2. Finegold S. M. (1986) Scand. J. Infect Dis. Suppl. 49, 160–164 [PubMed]
3. Kelly C. P., LaMont J. T. (1998) Annu. Rev. Med. 49, 375–390 [PubMed]
4. Voth D. E., Ballard J. D. (2005) Clin. Microbiol. Rev. 18, 247–263 [PMC free article] [PubMed]
5. Höltje J. V. (1998) Microbiol. Mol. Biol. Rev. 62, 181–203 [PMC free article] [PubMed]
6. Scheffers D. J., Pinho M. G. (2005) Microbiol. Mol. Biol. Rev. 69, 585–607 [PMC free article] [PubMed]
7. Sauvage E., Kerff F., Terrak M., Ayala J. A., Charlier P. (2008) FEMS Microbiol. Rev. 32, 234–258 [PubMed]
8. Zapun A., Contreras-Martel C., Vernet T. (2008) FEMS Microbiol. Rev. 32, 361–385 [PubMed]
9. Mainardi J. L., Villet R., Bugg T. D., Mayer C., Arthur M. (2008) FEMS Microbiol. Rev. 32, 386–408 [PubMed]
10. Mainardi J. L., Fourgeaud M., Hugonnet J. E., Dubost L., Brouard J. P., Ouazzani J., Rice L. B., Gutmann L., Arthur M. (2005) J. Biol. Chem. 280, 38146–38152 [PubMed]
11. Lavollay M., Arthur M., Fourgeaud M., Dubost L., Marie A., Riegel P., Gutmann L., Mainardi J. L. (2009) Mol. Microbiol 74, 650–661 [PubMed]
12. Magnet S., Arbeloa A., Mainardi J. L., Hugonnet J. E., Fourgeaud M., Dubost L., Marie A., Delfosse V., Mayer C., Rice L. B., Arthur M. (2007) J. Biol. Chem. 282, 13151–13159 [PubMed]
13. Lavollay M., Arthur M., Fourgeaud M., Dubost L., Marie A., Veziris N., Blanot D., Gutmann L., Mainardi J. L. (2008) J. Bacteriol. 190, 4360–4366 [PMC free article] [PubMed]
14. Lavollay M., Fourgeaud M., Herrmann J. L., Dubost L., Marie A., Gutmann L., Arthur M., Mainardi J. L. (2011) J. Bacteriol. 193, 778–782 [PMC free article] [PubMed]
15. Gupta R., Lavollay M., Mainardi J. L., Arthur M., Bishai W. R., Lamichhane G. (2010) Nat. Med. 16, 466–469 [PMC free article] [PubMed]
16. Magnet S., Bellais S., Dubost L., Fourgeaud M., Mainardi J. L., Petit-Frère S., Marie A., Mengin-Lecreulx D., Arthur M., Gutmann L. (2007) J. Bacteriol. 189, 3927–3931 [PMC free article] [PubMed]
17. Magnet S., Dubost L., Marie A., Arthur M., Gutmann L. (2008) J. Bacteriol. 190, 4782–4785 [PMC free article] [PubMed]
18. Mainardi J. L., Legrand R., Arthur M., Schoot B., van Heijenoort J., Gutmann L. (2000) J. Biol. Chem. 275, 16490–16496 [PubMed]
19. Vollmer W. (2008) FEMS Microbiol. Rev. 32, 287–306 [PubMed]
20. Bernard E., Rolain T., Courtin P., Guillot A., Langella P., Hols P., Chapot-Chartier M. P. (2011) J. Biol. Chem. 286, 23950–23958 [PMC free article] [PubMed]
21. Boneca I. G., Dussurget O., Cabanes D., Nahori M. A., Sousa S., Lecuit M., Psylinakis E., Bouriotis V., Hugot J. P., Giovannini M., Coyle A., Bertin J., Namane A., Rousselle J. C., Cayet N., Prévost M. C., Balloy V., Chignard M., Philpott D. J., Cossart P., Girardin S. E. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 997–1002 [PubMed]
22. Vollmer W., Tomasz A. (2002) Infect Immun. 70, 7176–7178 [PMC free article] [PubMed]
23. Bera A., Herbert S., Jakob A., Vollmer W., Götz F. (2005) Mol. Microbiol. 55, 778–787 [PubMed]
24. Citron D. M., Merriam C. V., Tyrrell K. L., Warren Y. A., Fernandez H., Goldstein E. J. (2003) Antimicrob. Agents Chemother. 47, 2334–2338 [PMC free article] [PubMed]
25. Sebaihia M., Wren B. W., Mullany P., Fairweather N. F., Minton N., Stabler R., Thomson N. R., Roberts A. P., Cerdeño-Tárraga A. M., Wang H., Holden M. T., Wright A., Churcher C., Quail M. A., Baker S., Bason N., Brooks K., Chillingworth T., Cronin A., Davis P., Dowd L., Fraser A., Feltwell T., Hance Z., Holroyd S., Jagels K., Moule S., Mungall K., Price C., Rabbinowitsch E., Sharp S., Simmonds M., Stevens K., Unwin L., Whithead S., Dupuy B., Dougan G., Barrell B., Parkhill J. (2006) Nat. Genet. 38, 779–786 [PubMed]
26. Hussain H. A., Roberts A. P., Mullany P. (2005) J. Med. Microbiol. 54, 137–141 [PubMed]
27. Courtin P., Miranda G., Guillot A., Wessner F., Mézange C., Domakova E., Kulakauskas S., Chapot-Chartier M. P. (2006) J. Bacteriol. 188, 5293–5298 [PMC free article] [PubMed]
28. Heap J. T., Pennington O. J., Cartman S. T., Carter G. P., Minton N. P. (2007) J. Microbiol. Methods 70, 452–464 [PubMed]
29. Vollmer W., Blanot D., de Pedro M. A. (2008) FEMS Microbiol. Rev. 32, 149–167 [PubMed]
30. Bielnicki J., Devedjiev Y., Derewenda U., Dauter Z., Joachimiak A., Derewenda Z. S. (2006) Proteins 62, 144–151 [PMC free article] [PubMed]
31. Depardieu F., Bonora M. G., Reynolds P. E., Courvalin P. (2003) Mol. Microbiol. 50, 931–948 [PubMed]
32. Dhalluin A., Bourgeois I., Pestel-Caron M., Camiade E., Raux G., Courtin P., Chapot-Chartier M. P., Pons J. L. (2005) Microbiology 151, 2343–2351 [PubMed]
33. Schleifer K. H., Kandler O. (1972) Bacteriol. Rev. 36, 407–477 [PMC free article] [PubMed]
34. Collins M. D., Lawson P. A., Willems A., Cordoba J. J., Fernandez-Garayzabal J., Garcia P., Cai J., Hippe H., Farrow J. A. (1994) Int. J. Syst. Bacteriol. 44, 812–826 [PubMed]
35. Zipperle G. F., Jr., Ezzell J. W., Jr., Doyle R. J. (1984) Can. J. Microbiol. 30, 553–559 [PubMed]
36. Atrih A., Bacher G., Allmaier G., Williamson M. P., Foster S. J. (1999) J. Bacteriol. 181, 3956–3966 [PMC free article] [PubMed]
37. Vollmer W., Tomasz A. (2000) J. Biol. Chem. 275, 20496–20501 [PubMed]
38. Psylinakis E., Boneca I. G., Mavromatis K., Deli A., Hayhurst E., Foster S. J., Vårum K. M., Bouriotis V. (2005) J. Biol. Chem. 280, 30856–30863 [PubMed]
39. Pisabarro A. G., de Pedro M. A., Vázquez D. (1985) J. Bacteriol. 161, 238–242 [PMC free article] [PubMed]
40. Warth A. D., Strominger J. L. (1972) Biochemistry 11, 1389–1396 [PubMed]
41. Atrih A., Zöllner P., Allmaier G., Foster S. J. (1996) J. Bacteriol. 178, 6173–6183 [PMC free article] [PubMed]
42. Mainardi J. L., Morel V., Fourgeaud M., Cremniter J., Blanot D., Legrand R., Frehel C., Arthur M., Van Heijenoort J., Gutmann L. (2002) J. Biol. Chem. 277, 35801–35807 [PubMed]
43. Sacco E., Hugonnet J. E., Josseaume N., Cremniter J., Dubost L., Marie A., Patin D., Blanot D., Rice L. B., Mainardi J. L., Arthur M. (2010) Mol. Microbiol. 75, 874–885 [PubMed]
44. Glauner B., Höltje J. V., Schwarz U. (1988) J. Biol. Chem. 263, 10088–10095 [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology